Leerink Partnrs Boosts Earnings Estimates for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of $1.29 for the year, up from their previous estimate of $1.15. The consensus estimate for Genmab A/S’s current full-year earnings is $1.31 per share. Leerink Partnrs also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.40 EPS and FY2025 earnings at $1.58 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the firm earned $0.47 EPS.

GMAB has been the topic of several other reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Stock Up 0.5 %

NASDAQ GMAB opened at $23.20 on Monday. Genmab A/S has a twelve month low of $21.90 and a twelve month high of $32.89. The stock has a market cap of $15.35 billion, a P/E ratio of 22.50, a PEG ratio of 0.68 and a beta of 0.99. The company’s 50-day simple moving average is $24.39 and its 200 day simple moving average is $26.38.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S during the first quarter worth $43,000. Blue Trust Inc. lifted its stake in shares of Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its position in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.